FDA clears Medtronic Protecta ICDs, CRT-Ds

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon

The FDA has approved Medtronic’s Protecta portfolio of implantable cardioverter-defibrillators (ICDs) and cardiac resynchronization therapy-defibrillators (CRT-Ds).

The new family of implantable defibrillators features SmartShock Technology, which includes six new Medtronic algorithms for arrhythmia recognition that deliver therapeutic shocks only when appropriate, according to the Minneapolis-based company. They include Wavelet + PR Logic, SVT discrimination in the VF zone and Confirmation; T-wave Discrimination and Lead Noise Discrimination; and Lead Integrity Alert, first released in 2008.

Shipments of the Protecta portfolio will begin immediately.